Dementia, a progressive cognitive decline, leads to a gradually increasing restriction of daily activities. Alzheimer's disease (AD) is the most common form of dementia. The pathological features of AD include plaques and tangles which are constituted by amyloid β peptide (Aβ ) and tau protein. These amyloidogenic molecules have been mechanistically implicated in the pathogenesis of AD and related neurodegenerative dementias. The key strategy for establishment of diagnostic and therapeutic approaches to AD is sensitive and specific detection of the incipient neuropathology characteristics of AD, combined with emerging treatments that counteract molecular processes in AD pathogenesis. Recent advances in molecular imaging research have enabled visualization of brain amyloidosis. The rapid development of different compounds suitable for visualizing amyloid would permit pathology-specific diagnosis of AD at an asymptomatic stage in a noninvasive manner, and could also allow early immunotherapeutic intervention without causing an excessive neuroinflammatory response.
Dementia, a progressive cognitive decline, leads to a gradually increasing restriction of daily activities. About 6% of the population over 65 years old is afflicted with dementia, and the number of new cases in 2000 was estimated to be 4-6 million worldwide (Wimo et al. 2003) . Dementia not only affects the patients themselves but also has substantial negative impacts on their families and society, as most patients require long-term care at home by family members, which can often last 5 -20 years or longer. Solution of these critical social issues is intimately associated with establishment of diagnostic and therapeutic approaches to Alzheimer's disease (AD), the most common type of dementia. The key strategy for this achievement is sensitive and specific detection of the incipient neuropathology characteristics of AD, combined with emerging treatments that counteract molecular processes in AD pathogenesis. Conventional neuroimaging-based measures as exemplified by morphometric indices, regional cerebral blood flow and glucose metabolism have offered informative adjuncts in predicting symptomatic conversion of minor memory and other cognitive disturbances, collectively termed mild cognitive impairment, to clinically tex to all cortical areas. In consideration of this putative spatiotemporal profile, observation of widespread tangles and plaque formation in preclinical AD brains (Price and Morris 1999) strongly indicates that occurrence of amyloid aggregates long precedes cognitive deterioration, presumably by decades.
In addition to the clinicopathological findings in human subjects, genetically engineered mouse models of familial dementias have provided an insight into the pathophysiological significance of amyloid fibrillogenesis in the devastating effects of AD and other degenerative disorders (Walsh et al. 2002; Higuchi et al. 2002b; Lewis et al. 2001; Masliah et al. 2001) . Of particular importance is the fact that these animals are also useful for preclinical tests of diagnostic and therapeutic agents targeting amyloidosis. Moreover, appropriate disease models in conjunction with small animal-dedicated imaging systems could facilitate the efficient development of amyloid probes and anti-amyloid treatments, as they allow comparative evaluation of multiple candidate tracers and longitudinal assessments of neuropathology along the course of therapeutic intervention. Proof of the mechanistic concept of antiamyloid treatments in animals would further clarify the attribution of neurodegeneration to amyloidogenesis.
Amyloid imaging
A great number of investigations have attempted to detect brain amyloid by means of imaging technologies, mostly with the assistance of specific probes. Because the β -pleated sheet is a secondary structure commonly shared by amyloid lesions, chemicals that bind to β -sheets would make good candidates for a tracer compound. Among such chemicals, Congo red and thioflavin-T are well-known dyes that stain with a wide range of amyloid pathologies. However, these compounds are not applicable as intravenously administrable tracers for amyloid imaging, because they do not pass the blood-brain barrier (BBB). Thus, smaller and/or uncharged derivatives of Congo red and thioflavin-T have been developed for BBB permeability, and radiolabeled diagnosable AD. Meanwhile, recent advances in molecular imaging research have enabled visualization of brain amyloidosis, the core pathology of AD, potentially permitting presymptomatic diagnosis and initiation of disease-modifying therapies.
Pathological signatures and molecular etiology of Alzheimer's disease
The presence of amyloid lesions, comprised of senile plaques and neurofibrillar tangles, is a neuropathological hallmark of the AD brain (Higuchi et al. 2004) . Amyloid β peptide (Aβ ) and tau protein constitute plaques and tangles, respectively, and these amyloidogenic molecules have been mechanistically implicated in the pathogenesis of AD and related neurodegenerative dementias. Indeed, numerous investigations have supported the notion that cascade reactions of molecular processes triggered by aberrancy of amyloidogenic components involve synaptic loss and neurotransmitter deficits, eventually leading to neuronal death and cognitive impairments. The most crucial evidence for the causal links between amyloidosis and neurodegeneration has been provided by the discovery of genetic mutations in familial forms of neurodegenerative diseases. Mutations of genes coding amyloid precursor protein (APP) and presenilin result in familial AD primarily via overproduction of Aβ (Saido 2003) , and mutant tau proteins either exhibit a propensity to self-assemble or are defective in stabilizing axonal cytoskeletons, giving rise to a hereditary form of frontotemporal dementia (FTLD) and p a r k i n s o n i s m l i n k e d t o c h r o m o s o m e 1 7 (FTDP-17) (Higuchi et al. 2002a) .
Accumulating documentation of the initialization of the neurotoxic cascade by amyloid fibrils has reinforced the rationale for applying in vivo amyloid imaging to the detection of AD pathology at a prodromal stage. Appearance of amyloid deposits antecedent to symptomatic onset has also been demonstrated by neuropathological analyses of postmortem AD brains. As Braak and Braak (1991) proposed on the basis of their pathological staging of brain amyloidosis, amyloid deposits appear to spread from the basal neocor-versions of these amyloid ligands are used for positron emission tomography (PET) and singlephoton emission tomography (Sair et al. 2004; Klunk et al. 2004) .
Some of the synthesized derivatives of thioflavin, such as 125 I-6 (Wang et al. 2002), 3 H-BTA-1 (Klunk et al. 2003) and 11 C-6-OH-BTA-1 (also known as Pittsburgh Compound-B [PIB]), have promising binding properties with affinities for Ab amyloid in a nanomolar range (Fig. 1) . In vitro studies have also demonstrated consistency in the amounts of PIB binding sites and biochemically measured Aβ in frontal cortex samples from autopsied AD brains (Näslund et al. 2000) . Since the first report on the application of PIB for the differentiation between nondemented subjects and AD patients (Klunk et al. 2004 ), PIB and several other radioligands have been shown to be of great utility for detection of amyloid at early symptomatic Rowe et al. 2007 ) and possibly presymptomatic (Mintun et al. 2006; ) stages of AD.
Despite these clinical data, PET experiments using animal models did not provide unequivocal evidence that radiolabeled compounds administered at an imaging dose bind specifically to brain amyloid, as Aβ plaques have only been marginally captured in PET analyses of APP transgenic (Tg) mouse brains Toyama et al. 2005) . To overcome the insensitivity of amyloid detection in mice, we have recently attempted to use PIB synthesized with high specific radioactivity (SA), which supposedly enables the detectability of unabundant binding sites, and have successfully performed PET visualization of progressively depositing Aβ aggregates in brains of APP Tg mice (Maeda et al. 2007a ). In addition, our in vitro assays revealed preferential binding of PIB to N-terminally modified Aβ , Aβ -N3-pyroglutamate (Maeda et al. 2007a ). Interestingly, Aβ -N3-pyroglutamate is known to be a major constituent of pathological Aβ deposits in AD brains (Saido et al. 1995) and more prone to fibrillization than unmodified species (He and Barrow 1999; Schilling et al. 2006) , and has been critically implicated in Aβ -induced neurotoxicity (Rosso et al. 2002; Wirths et al. 2007a, b) . As levels of this Aβ subspecies in model mice are m u c h l o w e r t h a n t h o s e i n A D p a t i e n t s (Kawarabayashi et al. 2001; Güntert et al. 2006) , these findings plausibly explain the advantages of high-SA tracers in the sensitive detection of mouse amyloid, and highlight the significance of Aβ -N3-pyroglutamate as a new diagnostic and therapeutic target. The established animal system has been applied to a comparison of multiple radiotracers, such as PIB and 11 C-BF-227 (Kudo et al. 2007 ), in a collaborative work with Tohoku University, and was proven to facilitate the preclinical selection of PET imaging agents adequate for specific purposes, including early detection of amyloid formation, assessment of pathological progression and evaluation of therapeutic effects. Multitracer, multi-scan PET study is also of pivotal importance in the mechanistic evaluation of Aβ immunization and other related anti-amyloid treatments, as a PET ligand for peripheral benzodiazepine receptor, termed [
18 F]fluoroethyl-DAA1106, which we recently developed for capturing glial activation (Zhang et al. 2004; Maeda et al. 2007b) , can be used in combination with amyloid probes to longitudinally assess the contribution of neuroinflammation to both therapeutic and adverse effects. Activation of microglia has been suggested to be engaged in the production or phagocytosis of amyloid (el Hachimi and Foncin 1994) . Another role of microglia was reported in the amyloid related inflammation and toxity and subsequent secondary tissue damage (Barger and Harmon 1997; Tan et al. 1999) . Taking this into consideration, the outcomes of Aβ immunization were evaluated by paralleling PET assays of activated microglia and amyloid (Maeda et al. 2007a) . Notably, near-simultaneous monitoring of amyloid removal and microgliosis in APP Tg mice following injection of anti-Aβ antibody demonstrated positive correlation between levels of initially existing amyloid and antibody-induced microglial activation, suggesting the possibility of microglial overactivation in immunotherapy for subjects with abundant amyloid (Maeda et al. 2007a) . Because excessive microglial activation has been shown to accelerate tau pathology in our recent observations of Tg mice overexpressing the FTDP-17 tau mutation (Yoshiyama et al. 2007 ), it seems necessary for microglial activity to be stringently regulated within an adequate range during the course of anti-amyloid treatments by longitudinal PET monitoring. (Fig. 2) 
CONCLUSION AND PERSPECTIVE
Establishment of radiolabeled tracers optimized for in vivo imaging of Aβ plaques would permit pathology-specific diagnosis of AD at an asymptomatic stage in a noninvasive manner, and could also allow early immunotherapeutic intervention without causing an excessive neuroinflammatory response. While various strategies for suppressing amyloidogenesis have been demonstrated to work in animal models, it remains to be examined whether the efficacy of these antiamyloid treatments can be monitored with the aid of amyloid imaging, in view of the differences in the biochemical composition of Aβ deposits between AD patients and APP Tg mice. The utility of imaging agents for microglial activation, altered neurotransmission and other key processes downstream of amyloid formation should also be taken into account in order to therapeutically regulate the entire pathological cascade of AD.
